Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007-02 study.
暂无分享,去创建一个
P. Moreau | H. Avet-Loiseau | G. Marit | T. Facon | J. Harousseau | C. Doyen | M. Attal | L. Garderet | M. Tiab | C. Hulin